CN101195647B - 羟基红花黄色素a及其制备方法和应用 - Google Patents
羟基红花黄色素a及其制备方法和应用 Download PDFInfo
- Publication number
- CN101195647B CN101195647B CN2006101609597A CN200610160959A CN101195647B CN 101195647 B CN101195647 B CN 101195647B CN 2006101609597 A CN2006101609597 A CN 2006101609597A CN 200610160959 A CN200610160959 A CN 200610160959A CN 101195647 B CN101195647 B CN 101195647B
- Authority
- CN
- China
- Prior art keywords
- hydroxyl radical
- carthamin yellow
- radical carthamin
- yellow carthamus
- column
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Active
Links
- 238000002360 preparation method Methods 0.000 title claims abstract description 18
- 244000020518 Carthamus tinctorius Species 0.000 title abstract description 18
- 235000003255 Carthamus tinctorius Nutrition 0.000 title abstract description 18
- 125000002887 hydroxy group Chemical group [H]O* 0.000 title 1
- 238000000034 method Methods 0.000 claims abstract description 36
- 238000004440 column chromatography Methods 0.000 claims abstract description 30
- 239000007788 liquid Substances 0.000 claims abstract description 12
- 238000000605 extraction Methods 0.000 claims abstract description 6
- WLYGSPLCNKYESI-RSUQVHIMSA-N Carthamin Chemical compound O[C@@H]1[C@@H](O)[C@H](O)[C@@H](CO)O[C@H]1[C@@]1(O)C(O)=C(C(=O)\C=C\C=2C=CC(O)=CC=2)C(=O)C(\C=C\2C([C@](O)([C@H]3[C@@H]([C@@H](O)[C@H](O)[C@@H](CO)O3)O)C(O)=C(C(=O)\C=C\C=3C=CC(O)=CC=3)C/2=O)=O)=C1O WLYGSPLCNKYESI-RSUQVHIMSA-N 0.000 claims description 209
- DYQVDISPPLTLLR-HJQYTNQXSA-N Carthamin Natural products CC[C@H]1O[C@H]([C@H](O)[C@@H](O)[C@@H]1O)[C@]2(O)C(=C(C=C/3C(=O)C(=C(O)[C@](O)([C@@H]4O[C@H](CO)[C@@H](O)[C@H](O)[C@H]4O)C3=O)C(=O)C=Cc5ccc(O)cc5)C(=O)C(=C2O)C(=O)C=Cc6ccc(O)cc6)O DYQVDISPPLTLLR-HJQYTNQXSA-N 0.000 claims description 110
- 241000208809 Carthamus Species 0.000 claims description 101
- TUJKJAMUKRIRHC-UHFFFAOYSA-N hydroxyl Chemical compound [OH] TUJKJAMUKRIRHC-UHFFFAOYSA-N 0.000 claims description 100
- XLYOFNOQVPJJNP-UHFFFAOYSA-N water Substances O XLYOFNOQVPJJNP-UHFFFAOYSA-N 0.000 claims description 35
- 239000000843 powder Substances 0.000 claims description 27
- 239000011347 resin Substances 0.000 claims description 26
- 229920005989 resin Polymers 0.000 claims description 26
- 238000006243 chemical reaction Methods 0.000 claims description 16
- 239000006228 supernatant Substances 0.000 claims description 14
- 239000001052 yellow pigment Substances 0.000 claims description 14
- LFQSCWFLJHTTHZ-UHFFFAOYSA-N Ethanol Chemical compound CCO LFQSCWFLJHTTHZ-UHFFFAOYSA-N 0.000 claims description 12
- 239000000284 extract Substances 0.000 claims description 11
- 238000001035 drying Methods 0.000 claims description 10
- 238000005516 engineering process Methods 0.000 claims description 9
- 238000005507 spraying Methods 0.000 claims description 9
- 238000010828 elution Methods 0.000 claims description 8
- FEMOMIGRRWSMCU-UHFFFAOYSA-N ninhydrin Chemical compound C1=CC=C2C(=O)C(O)(O)C(=O)C2=C1 FEMOMIGRRWSMCU-UHFFFAOYSA-N 0.000 claims description 7
- 241000628997 Flos Species 0.000 claims description 6
- 229920005654 Sephadex Polymers 0.000 claims description 4
- 239000012507 Sephadex™ Substances 0.000 claims description 4
- 238000001914 filtration Methods 0.000 claims description 4
- 239000011521 glass Substances 0.000 claims description 4
- 208000026106 cerebrovascular disease Diseases 0.000 abstract description 16
- 239000003814 drug Substances 0.000 abstract description 11
- IAVUBSCVWHLRGE-UXEKTNMQSA-N (6e)-2,5-dihydroxy-6-[(e)-1-hydroxy-3-(4-hydroxyphenyl)prop-2-enylidene]-2,4-bis[(2s,3r,4r,5s,6r)-3,4,5-trihydroxy-6-(hydroxymethyl)oxan-2-yl]cyclohex-4-ene-1,3-dione Chemical compound O[C@@H]1[C@@H](O)[C@H](O)[C@@H](CO)O[C@H]1C(C(C(O)([C@H]1[C@@H]([C@@H](O)[C@H](O)[C@@H](CO)O1)O)C1=O)=O)=C(O)\C1=C(/O)\C=C\C1=CC=C(O)C=C1 IAVUBSCVWHLRGE-UXEKTNMQSA-N 0.000 abstract description 8
- ZZMASNSDVDSYKO-UHFFFAOYSA-N hydroxysafflor yellow A Natural products OCC1OC(C(O)C(O)C1O)C2=C(O)C(O)(C3OC(CO)C(O)C(O)C3O)C(=O)C(=C2O)C(=O)C=Cc4ccc(O)cc4 ZZMASNSDVDSYKO-UHFFFAOYSA-N 0.000 abstract description 8
- 238000004587 chromatography analysis Methods 0.000 abstract description 5
- 208000000386 Hypertensive Intracranial Hemorrhage Diseases 0.000 abstract description 4
- 229940079593 drug Drugs 0.000 abstract description 3
- 238000011031 large-scale manufacturing process Methods 0.000 abstract description 2
- 230000002490 cerebral effect Effects 0.000 abstract 1
- 239000000463 material Substances 0.000 abstract 1
- 229940119485 safflower extract Drugs 0.000 abstract 1
- 239000000243 solution Substances 0.000 description 26
- 239000007924 injection Substances 0.000 description 14
- 238000002347 injection Methods 0.000 description 14
- 230000000694 effects Effects 0.000 description 13
- 239000000203 mixture Substances 0.000 description 13
- 238000009472 formulation Methods 0.000 description 12
- 206010008118 cerebral infarction Diseases 0.000 description 10
- 238000004519 manufacturing process Methods 0.000 description 10
- 239000003463 adsorbent Substances 0.000 description 9
- 239000008354 sodium chloride injection Substances 0.000 description 9
- 102000004169 proteins and genes Human genes 0.000 description 8
- 108090000623 proteins and genes Proteins 0.000 description 8
- 238000005303 weighing Methods 0.000 description 8
- FBPFZTCFMRRESA-KVTDHHQDSA-N D-Mannitol Chemical compound OC[C@@H](O)[C@@H](O)[C@H](O)[C@H](O)CO FBPFZTCFMRRESA-KVTDHHQDSA-N 0.000 description 6
- 229930195725 Mannitol Natural products 0.000 description 6
- 150000004676 glycans Chemical class 0.000 description 6
- 239000000594 mannitol Substances 0.000 description 6
- 235000010355 mannitol Nutrition 0.000 description 6
- 229920001282 polysaccharide Polymers 0.000 description 6
- 239000005017 polysaccharide Substances 0.000 description 6
- 239000000047 product Substances 0.000 description 6
- 238000000746 purification Methods 0.000 description 6
- 150000001408 amides Chemical class 0.000 description 5
- 239000012535 impurity Substances 0.000 description 5
- 238000001556 precipitation Methods 0.000 description 5
- 230000011218 segmentation Effects 0.000 description 5
- 238000000926 separation method Methods 0.000 description 5
- 229920002472 Starch Polymers 0.000 description 4
- 230000001154 acute effect Effects 0.000 description 4
- 239000006286 aqueous extract Substances 0.000 description 4
- 238000004108 freeze drying Methods 0.000 description 4
- HQKMJHAJHXVSDF-UHFFFAOYSA-L magnesium stearate Chemical compound [Mg+2].CCCCCCCCCCCCCCCCCC([O-])=O.CCCCCCCCCCCCCCCCCC([O-])=O HQKMJHAJHXVSDF-UHFFFAOYSA-L 0.000 description 4
- 230000002265 prevention Effects 0.000 description 4
- 235000019698 starch Nutrition 0.000 description 4
- 239000008107 starch Substances 0.000 description 4
- 238000012360 testing method Methods 0.000 description 4
- 238000003809 water extraction Methods 0.000 description 4
- JGSARLDLIJGVTE-UHFFFAOYSA-N 3,3-dimethyl-7-oxo-6-[(2-phenylacetyl)amino]-4-thia-1-azabicyclo[3.2.0]heptane-2-carboxylic acid Chemical compound O=C1N2C(C(O)=O)C(C)(C)SC2C1NC(=O)CC1=CC=CC=C1 JGSARLDLIJGVTE-UHFFFAOYSA-N 0.000 description 3
- XAGFODPZIPBFFR-UHFFFAOYSA-N aluminium Chemical compound [Al] XAGFODPZIPBFFR-UHFFFAOYSA-N 0.000 description 3
- 229910052782 aluminium Inorganic materials 0.000 description 3
- 239000004411 aluminium Substances 0.000 description 3
- 239000002775 capsule Substances 0.000 description 3
- 150000001720 carbohydrates Chemical class 0.000 description 3
- 235000014633 carbohydrates Nutrition 0.000 description 3
- -1 chalcone compound Chemical class 0.000 description 3
- 239000000470 constituent Substances 0.000 description 3
- 238000007796 conventional method Methods 0.000 description 3
- 239000000706 filtrate Substances 0.000 description 3
- 238000009776 industrial production Methods 0.000 description 3
- 230000002452 interceptive effect Effects 0.000 description 3
- 238000004811 liquid chromatography Methods 0.000 description 3
- 238000012856 packing Methods 0.000 description 3
- 238000011146 sterile filtration Methods 0.000 description 3
- 230000001954 sterilising effect Effects 0.000 description 3
- 238000004659 sterilization and disinfection Methods 0.000 description 3
- 238000003756 stirring Methods 0.000 description 3
- 239000000126 substance Substances 0.000 description 3
- 239000008215 water for injection Substances 0.000 description 3
- 208000024172 Cardiovascular disease Diseases 0.000 description 2
- 208000004552 Lacunar Stroke Diseases 0.000 description 2
- 206010051078 Lacunar infarction Diseases 0.000 description 2
- 208000006011 Stroke Diseases 0.000 description 2
- 238000010521 absorption reaction Methods 0.000 description 2
- 230000000274 adsorptive effect Effects 0.000 description 2
- 230000017531 blood circulation Effects 0.000 description 2
- 210000004004 carotid artery internal Anatomy 0.000 description 2
- 238000000975 co-precipitation Methods 0.000 description 2
- 239000012141 concentrate Substances 0.000 description 2
- 238000003795 desorption Methods 0.000 description 2
- 230000002526 effect on cardiovascular system Effects 0.000 description 2
- 230000003203 everyday effect Effects 0.000 description 2
- 238000001990 intravenous administration Methods 0.000 description 2
- 238000011068 loading method Methods 0.000 description 2
- 235000019359 magnesium stearate Nutrition 0.000 description 2
- 238000002156 mixing Methods 0.000 description 2
- 230000010118 platelet activation Effects 0.000 description 2
- 238000007781 pre-processing Methods 0.000 description 2
- 238000007639 printing Methods 0.000 description 2
- 238000001179 sorption measurement Methods 0.000 description 2
- 239000003826 tablet Substances 0.000 description 2
- 230000001225 therapeutic effect Effects 0.000 description 2
- 241000894006 Bacteria Species 0.000 description 1
- 206010008190 Cerebrovascular accident Diseases 0.000 description 1
- DQFBYFPFKXHELB-UHFFFAOYSA-N Chalcone Natural products C=1C=CC=CC=1C(=O)C=CC1=CC=CC=C1 DQFBYFPFKXHELB-UHFFFAOYSA-N 0.000 description 1
- 235000008495 Chrysanthemum leucanthemum Nutrition 0.000 description 1
- 244000192528 Chrysanthemum parthenium Species 0.000 description 1
- 235000000604 Chrysanthemum parthenium Nutrition 0.000 description 1
- 241000721047 Danaus plexippus Species 0.000 description 1
- 208000001953 Hypotension Diseases 0.000 description 1
- 206010062016 Immunosuppression Diseases 0.000 description 1
- 239000004480 active ingredient Substances 0.000 description 1
- 238000004458 analytical method Methods 0.000 description 1
- 230000003042 antagnostic effect Effects 0.000 description 1
- 230000008485 antagonism Effects 0.000 description 1
- 239000003963 antioxidant agent Substances 0.000 description 1
- 230000003078 antioxidant effect Effects 0.000 description 1
- 235000006708 antioxidants Nutrition 0.000 description 1
- 230000009286 beneficial effect Effects 0.000 description 1
- 239000008280 blood Substances 0.000 description 1
- 210000004369 blood Anatomy 0.000 description 1
- 210000004556 brain Anatomy 0.000 description 1
- 235000005513 chalcones Nutrition 0.000 description 1
- 230000004087 circulation Effects 0.000 description 1
- 238000002591 computed tomography Methods 0.000 description 1
- 210000004351 coronary vessel Anatomy 0.000 description 1
- 238000003745 diagnosis Methods 0.000 description 1
- 230000000916 dilatatory effect Effects 0.000 description 1
- 239000003480 eluent Substances 0.000 description 1
- 238000011156 evaluation Methods 0.000 description 1
- 235000008384 feverfew Nutrition 0.000 description 1
- 239000012467 final product Substances 0.000 description 1
- 239000000796 flavoring agent Substances 0.000 description 1
- 235000019634 flavors Nutrition 0.000 description 1
- PCHJSUWPFVWCPO-UHFFFAOYSA-N gold Chemical group [Au] PCHJSUWPFVWCPO-UHFFFAOYSA-N 0.000 description 1
- 239000007902 hard capsule Substances 0.000 description 1
- 208000021822 hypotensive Diseases 0.000 description 1
- 230000001077 hypotensive effect Effects 0.000 description 1
- 230000001506 immunosuppresive effect Effects 0.000 description 1
- 208000028867 ischemia Diseases 0.000 description 1
- 230000000302 ischemic effect Effects 0.000 description 1
- 210000004185 liver Anatomy 0.000 description 1
- 210000004165 myocardium Anatomy 0.000 description 1
- 229940100691 oral capsule Drugs 0.000 description 1
- 230000003119 painkilling effect Effects 0.000 description 1
- 239000002245 particle Substances 0.000 description 1
- 239000002831 pharmacologic agent Substances 0.000 description 1
- 230000000144 pharmacologic effect Effects 0.000 description 1
- 230000001737 promoting effect Effects 0.000 description 1
- 238000010926 purge Methods 0.000 description 1
- 238000007670 refining Methods 0.000 description 1
- 150000003839 salts Chemical class 0.000 description 1
- 238000001694 spray drying Methods 0.000 description 1
- 238000002636 symptomatic treatment Methods 0.000 description 1
Images
Landscapes
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
Abstract
Description
制备方法 | 羟基红花黄色素A的含量 | 羟基红花黄色素A的收率 |
CN1475272 | 99.2% | 1.06% |
本发明申请 | 99.5% | 52.5% |
Claims (5)
Priority Applications (1)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
CN2006101609597A CN101195647B (zh) | 2006-12-06 | 2006-12-06 | 羟基红花黄色素a及其制备方法和应用 |
Applications Claiming Priority (1)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
CN2006101609597A CN101195647B (zh) | 2006-12-06 | 2006-12-06 | 羟基红花黄色素a及其制备方法和应用 |
Publications (2)
Publication Number | Publication Date |
---|---|
CN101195647A CN101195647A (zh) | 2008-06-11 |
CN101195647B true CN101195647B (zh) | 2010-08-18 |
Family
ID=39546291
Family Applications (1)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
CN2006101609597A Active CN101195647B (zh) | 2006-12-06 | 2006-12-06 | 羟基红花黄色素a及其制备方法和应用 |
Country Status (1)
Country | Link |
---|---|
CN (1) | CN101195647B (zh) |
Families Citing this family (13)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
CN102675379B (zh) * | 2011-03-15 | 2015-08-19 | 河北以岭医药研究院有限公司 | 一种从红花中提取精制羟基红花黄色素a的方法 |
CN102382151A (zh) * | 2011-09-08 | 2012-03-21 | 成都中医药大学 | 红花黄色素的分离纯化方法 |
CN102702150B (zh) * | 2012-06-19 | 2014-09-17 | 浙江永宁药业股份有限公司 | 一种羟基红花黄色素a的制备方法和应用 |
CN104230864A (zh) * | 2013-06-08 | 2014-12-24 | 浙江永宁药业股份有限公司 | 新的羟基红花黄色素a二价药用盐及其制备方法和用途 |
WO2014121666A1 (zh) | 2013-02-07 | 2014-08-14 | 浙江永宁药业股份有限公司 | 新的羟基红花黄色素药用盐 |
CN103980239B (zh) * | 2013-02-07 | 2016-04-13 | 浙江永宁药业股份有限公司 | 羟基红花黄色素a钠及其生产方法和用途 |
CN104721152B (zh) * | 2015-01-20 | 2017-10-17 | 哈尔滨医科大学 | 一种羟基红花黄色素a冻干粉针剂的制备方法及其产品 |
CN108084131A (zh) * | 2017-12-20 | 2018-05-29 | 泰州医药城国科化物生物医药科技有限公司 | 一种利用多糖基介质对羟基红花黄色素a富集纯化的方法 |
CN108084132A (zh) * | 2017-12-21 | 2018-05-29 | 华远医药研究院有限公司 | 高纯度羟基红花黄素a的提取方法 |
CN108395420B (zh) * | 2018-03-05 | 2023-03-21 | 上海诗丹德标准技术服务有限公司 | 一种羟基红花黄色素a的制备方法 |
CN115677638B (zh) * | 2018-12-25 | 2023-11-14 | 浙江永宁药业股份有限公司 | 红花黄色素及其在制备治疗心脑血管疾病药物中的应用 |
CN113816933B (zh) * | 2021-10-14 | 2024-02-09 | 北京悦康科创医药科技股份有限公司 | 一种羟基红花黄色素a的制备方法 |
CN116023356A (zh) * | 2021-10-26 | 2023-04-28 | 广州博济医药生物技术股份有限公司 | 羟基红花黄色素a的制备方法 |
Citations (3)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
CN1422616A (zh) * | 2001-12-06 | 2003-06-11 | 长春三真实业有限公司 | 羟基红花黄色素a在制备治疗、预防心脑血管疾病方面的药物用途 |
CN1475272A (zh) * | 2002-08-17 | 2004-02-18 | 李盛学 | 羟基红花黄色素a及其制备方法和应用 |
CN1640392A (zh) * | 2004-01-08 | 2005-07-20 | 山东绿叶天然药物研究开发有限公司 | 大剂量的羟基红花黄色素a或其可药用盐在缺血引起的急性脑中风的药物中的应用 |
-
2006
- 2006-12-06 CN CN2006101609597A patent/CN101195647B/zh active Active
Patent Citations (3)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
CN1422616A (zh) * | 2001-12-06 | 2003-06-11 | 长春三真实业有限公司 | 羟基红花黄色素a在制备治疗、预防心脑血管疾病方面的药物用途 |
CN1475272A (zh) * | 2002-08-17 | 2004-02-18 | 李盛学 | 羟基红花黄色素a及其制备方法和应用 |
CN1640392A (zh) * | 2004-01-08 | 2005-07-20 | 山东绿叶天然药物研究开发有限公司 | 大剂量的羟基红花黄色素a或其可药用盐在缺血引起的急性脑中风的药物中的应用 |
Also Published As
Publication number | Publication date |
---|---|
CN101195647A (zh) | 2008-06-11 |
Similar Documents
Publication | Publication Date | Title |
---|---|---|
CN101195647B (zh) | 羟基红花黄色素a及其制备方法和应用 | |
CN101099789A (zh) | 降血糖、降血脂和治疗血液病的地黄提取物及制备方法 | |
CN102772500B (zh) | 具有抗炎作用的热淋清颗粒原料头花蓼提取物 | |
CN102240322B (zh) | 一种复方丹参片及其制备工艺 | |
WO2020093510A1 (zh) | 一种灵芝孢子多糖的分离纯化方法 | |
CN101612188B (zh) | 杜仲降压中药缓释制剂的制备方法及产品 | |
CN103340983A (zh) | 黑果枸杞果实提取物及制备方法和应用 | |
CN102805767B (zh) | 具有抗***作用的热淋清颗粒原料头花蓼提取物 | |
CN107929544B (zh) | 白及属植物中militarine部位及单体的制备方法及其应用 | |
JP2002538214A (ja) | 心血管疾病治療用薬剤組成物及びその製造方法 | |
CN102100737B (zh) | 包含人参总皂苷与丹参总酚酸的药物组合物及其制备方法 | |
CN101549010B (zh) | 一种补骨脂总苷提取物的制备方法及应用 | |
CN108057064B (zh) | 一种延胡索总生物碱胃漂浮片 | |
CN1205216C (zh) | 富含红花明苷a的红花黄色素、其制备方法和含有它们的制剂及医药用途 | |
WO2014000119A1 (zh) | 一种抗快速性心律失常的制剂及其制备方法 | |
CN100444849C (zh) | 刺蒺藜提取物的新用途 | |
CN101618069B (zh) | 一种兼治瘀肿、出血和镇痛的胶囊制剂,其制备方法及用途 | |
CN104586904A (zh) | 一种同步分离制备锁阳多糖和锁阳黄酮的方法 | |
CN1943647A (zh) | 一种枇杷叶三萜酸提取物的制备方法 | |
CN1159326C (zh) | 老鹳草块根鞣酸的提取方法 | |
CN102018740A (zh) | 含有向日葵叶提取物的药物组合物及其用途 | |
CN101979021B (zh) | 一组具有抗氧化活性的复方提取物 | |
CN1554335A (zh) | 一种注射用丹红冻干粉针剂及其制备方法 | |
CN1264708A (zh) | 红花总黄色素及其制备方法和应用 | |
CN1194748C (zh) | 治疗高血压的药物及其制备方法 |
Legal Events
Date | Code | Title | Description |
---|---|---|---|
C06 | Publication | ||
PB01 | Publication | ||
C10 | Entry into substantive examination | ||
SE01 | Entry into force of request for substantive examination | ||
ASS | Succession or assignment of patent right |
Owner name: SHANXI HUAHUI KAIDE PHARMACEUTICAL CO.,LTD. Free format text: FORMER OWNER: YANG WEI Effective date: 20090911 |
|
C41 | Transfer of patent application or patent right or utility model | ||
TA01 | Transfer of patent application right |
Effective date of registration: 20090911 Address after: A, Shanxi Pharmaceutical Industrial Park, Jinzhong economic and Technological Development Zone, Shanxi, China: 030600 Applicant after: SHANXI HUAHUI KAIDE PHARMACEUTICAL Co.,Ltd. Address before: Room 2, building 1103, Building 29, No. 100029, North Third Ring Road, Beijing, Xicheng District, China Applicant before: Yang Wei |
|
C14 | Grant of patent or utility model | ||
GR01 | Patent grant | ||
C41 | Transfer of patent application or patent right or utility model | ||
TR01 | Transfer of patent right |
Effective date of registration: 20160223 Address after: 030600 A zone, Shanxi pharmaceutical industry park, Jinzhong economic and Technological Development Zone, Shanxi Patentee after: SHANXI DEYUANTANG PHARMACEUTICAL CO.,LTD. Address before: 030600 A zone, Shanxi Pharmaceutical Industrial Park, Jinzhong economic and Technological Development Zone, Shanxi Patentee before: SHANXI HUAHUI KAIDE PHARMACEUTICAL Co.,Ltd. |
|
PE01 | Entry into force of the registration of the contract for pledge of patent right | ||
PE01 | Entry into force of the registration of the contract for pledge of patent right |
Denomination of invention: Hydroxy safflower yellow pigment A and its preparation method and application Effective date of registration: 20220926 Granted publication date: 20100818 Pledgee: Bank of China Limited Jinzhong Branch Pledgor: SHANXI DEYUANTANG PHARMACEUTICAL CO.,LTD. Registration number: Y2022140000052 |